Antipsychotic Trials in Schizophrenia
The CATIE Project

This book presents the results of the landmark CATIE study, a long and comprehensive study of schizophrenia.

T. Scott Stroup (Edited by), Jeffrey A. Lieberman (Edited by)

9780521895330, Cambridge University Press

Hardback, published 1 April 2010

330 pages, 50 b/w illus.
24 x 2 x 16.1 cm, 0.7 kg

'This book is not just a reprint of all published CATIE papers - it takes us beyond the hype of the first publication by reminding us of the breadth and depth of the trial … This book will be of major interest to anyone involved in psychopharmacology. However, the richness of the use of social and cognitive end points means that there is a wealth of information for those who have no interest in antipsychotics but are interested in the lives and outcomes of people with schizophrenia.' The British Journal of Psychiatry

Antipsychotic medications are a key treatment for schizophrenia and sales of antipsychotic drugs approach $20 billion per year, with fierce marketing between the makers of the drugs. The U.S. National Institute of Mental Health sponsored the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project to provide independent information about the comparative effectiveness of medications. CATIE was the largest, longest and most comprehensive study of schizophrenia to date. Conducted under rigorous double-blind conditions, Antipsychotic Trials in Schizophrenia presents the definitive archival results of this landmark study. The core of the book consists of chapters focused on specific outcomes that set the CATIE findings in a wider context. Also included are chapters on the design, statistical analyses and implications for researchers, clinicians and policy makers. Psychiatrists, psychiatric researchers, mental health policy makers and those working in pharmaceutical companies will all find this to be essential reading.

List of contributors
Acknowledgements
Introduction
1. Study design and protocol development process T. Scott Stroup, Joseph P. McEvoy and Jeffrey A. Lieberman
2. Statistical considerations Sonia M. Davis, Gary G. Koch, Robert A. Rosenheck and Vicki G. Davis
3. Effectiveness and efficacy: staying on treatment and symptom reduction Joseph P. McEvoy, T. Scott Stroup and Jeffrey A. Lieberman
4. Cost-effectiveness and cost-benefit analysis Robert A. Rosenheck and Douglas L. Leslie
5. Psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study Marvin S. Swartz
6. Neurocognition Richard S. E. Keefe
7. Vocational outcomes Sandra G. Resnick and Robert A. Rosenheck
8. Family outcomes Deborah A. Perlick, Richard Kaczynski and Robert A. Rosenheck
9. Extrapyramidal side effects Stanley N. Caroff, Del D. Miller and Robert A. Rosenheck
10. Metabolic side effects and risk of cardiovascular disease Jonathan M. Meyer, Donald C. Goff and Joseph P. McEvoy
11. Substance use in persons with schizophrenia: incidence, baseline correlates, and effects on outcome Fred Reimherr, Marvin S. Swartz and John L. Olsen
12. Violence in schizophrenia: prevalence, correlates, and treatment effectiveness Jeffrey Swanson and Richard Van Dorn
13. Genetic investigations in the CATIE sample James J. Crowley and Patrick F. Sullivan
14. Human subjects considerations T. Scott Stroup and Paul Appelbaum
15. Population pharmacokinetics of antipsychotics Kristin L. Bigos, Robert R. Bies, Stephen R. Marder and Bruce G. Pollock
16. Implications for research design and study implementation T. Scott Stroup and Jeffrey A. Lieberman
17. Conclusion and implications for practice and policy Robert A. Rosenheck, T. Scott Stroup and Jeffrey A. Lieberman.

Subject Areas: Psychiatry [MMH], Psychopharmacology [MMGW], Clinical trials [MBGR1], Medical research [MBGR]